| 764248 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
952 Phase II trial of AV-GBM-1: dendritic cell vaccine pulsed with lysate enriched for autologous tumor-initiating cell antigens in the treatment of patients with newly diagnosed glioblastoma |
2021-11-01 |
10.1136/jitc-2021-sitc2021.952 |
Bota Daniela, Piccioni David, Duma Christopher, LaRocca Renato, Kesari Santosh, Abedi Mehrdad, Carrillo Jose, Aiken Robert, Hsu Frank, Kong Xiaotang, Taylor Thomas, Hsieh Candace, Nistor Gabriel, Dillman Robert |
| 764247 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
68 Rapid detection of somatic variants in human leukocyte antigen class 1 genes from solid tumor samples |
2021-11-01 |
10.1136/jitc-2021-sitc2021.068 |
Bharanikumar Ramit, Beutner Karl, Khan Aly, Perera Jason |
| 764246 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
421 A first-in-human (FIH) phase I/IIa clinical trial assessing a ribonucleic acid lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT |
2021-11-01 |
10.1136/jitc-2021-sitc2021.421 |
Linch Mark, Papai Zsuzsanna, Takacs Istvan, Imedio Esteban Rodrigo, Kühnle Marie-Cristine, Derhovanessian Evelyna, Vogler Isabel, Renken Stephanie, Graham Philippa, Sahin Ugur, Türeci Özlem |
| 764245 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
551 Pegasus Skin, a study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL2) with cemiplimab for the treatment of participants with advanced unresectable or metastatic skin cancers |
2021-11-01 |
10.1136/jitc-2021-sitc2021.551 |
John PARK, Baakili Adyb, Demers Brigitte, Saleem Rao, Gosselin Alice, Abbadessa Giovanni, Ascierto Paolo A |
| 764244 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
723 WTX-613, a conditionally activated IFNα INDUKINE™ molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models |
2021-11-01 |
10.1136/jitc-2021-sitc2021.723 |
Tyagi Ethika, Brodkin Heather, Canales Josue, Hicklin Dan, Ismail Nesreen, Morris Kristin, Nirschl Christopher, Salmeron Andres, Seidel-Dugan Cindy, Steiner Philipp, Steuert Zoe, Sullivan Jenna, Winston William |
| 764243 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
722 INBRX-121 is an NKp46-targeted detuned IL-2 with antitumor activity as a monotherapy or in combination with multiple cancer immunotherapy modalities |
2021-11-01 |
10.1136/jitc-2021-sitc2021.722 |
Sulzmaier Florian, Kinkead Heather, Polovina Anya, Kern Nadja, Sanabria Angelica, Macedo Chelsie, Hussain Abrahim, Ahn Sae Jeong, Pandit Rajay, Crago William, Timmer John, Heidt Analeah, Eckelman Brendan |
| 764242 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
721 Intratumoral immunotherapy with aluminum hydroxide-tethered IL-12 induces potent local and systemic immunity with minimal toxicity |
2021-11-01 |
10.1136/jitc-2021-sitc2021.721 |
Schmidt Michael, Papastoitsis Gregory, Kaufman Howard, Irvine Darrell, Wittrup K |
| 764241 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
720 CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies |
2021-11-01 |
10.1136/jitc-2021-sitc2021.720 |
Zhang Christie, Girgis Natasha, Merazga Zohra, Hatfield Steven, Histed Alex, Zhao Fan, Moniz Raymond, Yeung Kristin, Diaz Fulvio, Brown Jason, Haydock Mark, Witt Luke, Bautista Wynona, Ross John, Cemerski Saso, Suri Anish, Pienta Kenneth, Levisetti Matteo, Quayle Steve |
| 764240 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
719 XTX301, a protein-engineered IL-12, exhibits tumor-selective activity in mice without peripheral toxicities and is well tolerated in non-human primates |
2021-11-01 |
10.1136/jitc-2021-sitc2021.719 |
Patel Ekta, Malkova Natalia, Vu Sallyann, O'Donnell Rebekah, Fanny Manoussa, Guzman Wilson, Johnson Parker, McLaughlin Megan, Yerov Oleg, Jenkins Kurt, Madala Hanumantha Rao, O'Toole Caitlin, Pederzoli-Ribeil Magali, Chen Jia, Nicholson Benjamin, Avery Bill, Qiu Huawei, O'Hagan Ronan, O'Neil Jennifer |
| 764239 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
718 WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models |
2021-11-01 |
10.1136/jitc-2021-sitc2021.718 |
Nirschl Christopher, Brodkin Heather, Hicklin Daniel, Ismail Nesreen, Morris Kristin, Salmeron Andres, Seidel-Dugan Cindy, Steiner Philipp, Steuert Zoe, Sullivan Jenna, Winston William |
